Literature DB >> 34062007

Cohort profile: National Diabetes Audit for England and Wales.

N Holman1, P Knighton2, S H Wild3, N Sattar1, C Dew2, E W Gregg4, K Khunti5, J Valabhji6,7,8, B Young9.   

Abstract

The National Diabetes Audit (NDA) collates and analyses data on the quality and variation in clinical care and outcomes for people with diabetes. It also provides opportunities to assess trends, determinants, and outcomes of diabetes to help guide clinical and public health priorities. COHORT: Between 1st January 2003 and 31st March 2020 a total of 5,280,885 people diagnosed with diabetes were included in at least one NDA data collection. To this date, median follow up was 12 and 8 years for people with type 1 diabetes and type 2 diabetes respectively. Comparisons with the 2019/20 Quality and Outcomes Framework show it included 98% of adults in England and Wales with diagnosed type 1 and type 2 diabetes. Data includes demographic characteristics (age, sex, ethnicity, age at diagnosis, deprivation), risk factors (HbA1c, blood pressure, cholesterol, body mass index, smoking status) diabetic and cardiovascular complications and deaths. SECONDARY ANALYSIS: Secondary analyses have included: comparisons of HbA1c and blood pressure measurements in cohorts with similar characteristics to the Epidemiology of Diabetes Interventions and Complications study and the UK Prospective Diabetes Study; COVID-19 related mortality in people with Type 1 and Type 2 diabetes and incidence of Type 2 diabetes following admission to intensive care units. FUTURE PLANS: Commissioned NDA reports will continue to inform service development in England and Wales. The same data, with or without linkages to other external datasets, is also a rich resource for clinically orientated research. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  Diabetes; audit; cohort; dataset

Year:  2021        PMID: 34062007     DOI: 10.1111/dme.14616

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  2 in total

1.  Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit.

Authors:  Naomi Holman; Sarah H Wild; Kamlesh Khunti; Peter Knighton; Jackie O'Keefe; Chirag Bakhai; Bob Young; Naveed Sattar; Jonathan Valabhji; Edward W Gregg
Journal:  Diabetes Care       Date:  2022-05-01       Impact factor: 17.152

2.  Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy via Inhibition of TGF-β/Smad Pathway.

Authors:  George J Dugbartey; Quinsker L Wonje; Karl K Alornyo; Louis Robertson; Ismaila Adams; Vincent Boima; Samuel D Mensah
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.